Cargando…

Impact of denosumab on bone mass in cancer patients

Cancer therapy-induced bone loss (CTIBL) is a form of secondary osteoporosis associated with systemic chemotherapy and hormonal ablation therapy. The monitoring and treatment of CTIBL is an important component of comprehensive cancer care, especially for patients with curable disease and long life e...

Descripción completa

Detalles Bibliográficos
Autores principales:	Brown-Glaberman, Ursa, Stopeck, Alison T
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2013
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3707483/ https://www.ncbi.nlm.nih.gov/pubmed/23861604 http://dx.doi.org/10.2147/CPAA.S30330

Ejemplares similares

Role of denosumab in the management of skeletal complications in patients with bone metastases from solid tumors
por: Brown-Glaberman, Ursa, et al.
Publicado: (2012)

Circulating Carbonic Anhydrase IX and Antiangiogenic Therapy in Breast Cancer
por: Brown-Glaberman, Ursa, et al.
Publicado: (2016)

Response to letter to the Editors—Safety of long-term denosumab therapy
por: Stopeck, Alison T., et al.
Publicado: (2016)

Experience with denosumab (XGEVA®) for prevention of skeletal-related events in the 10 years after approval
por: Cadieux, Benoit, et al.
Publicado: (2022)

The Effect of Denosumab on Bone Mass in Super Elderly Patients
por: Jeong, Chaiho, et al.
Publicado: (2020)

Risk factors associated with skeletal-related events following discontinuation of denosumab treatment among patients with bone metastases from solid tumors: A real-world machine learning approach
por: Jacobson, Dionna, et al.
Publicado: (2022)

Management of bone metastases in refractory prostate cancer – role of denosumab
por: Paller, Channing J, et al.
Publicado: (2012)

Denosumab, a RANK ligand inhibitor, for the management of bone loss in cancer patients
por: Yee, Andrew J, et al.
Publicado: (2012)

Denosumab: a new option in the treatment of bone metastases from urological cancers
por: Yuasa, Takeshi, et al.
Publicado: (2012)

Cancer Treatment-Induced Bone Loss: Role of Denosumab in Non-Metastatic Breast Cancer
por: Dhabhar, Boman
Publicado: (2022)

Clinical utility of denosumab for treatment of bone loss in men and women
por: Adler, Robert A, et al.
Publicado: (2011)

Giant-cell tumor of bone: treatment options and role of denosumab
por: Singh, Arun S, et al.
Publicado: (2015)

Radiological findings of denosumab treatment for giant cell tumours of bone
por: van Langevelde, Kirsten, et al.
Publicado: (2020)

Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer
por: Stopeck, Alison T., et al.
Publicado: (2015)

Treatment-Induced Bone Loss and Fractures in Cancer Patients Undergoing Hormone Ablation Therapy: Efficacy and Safety of Denosumab
por: Lipton, Allan, et al.
Publicado: (2012)

Effect of risedronate on bone loss at discontinuation of denosumab
por: Laroche, Michel, et al.
Publicado: (2020)

Bone Health and Denosumab Discontinuation in Oncology Populations
por: Cheung, Yee-Ming Melody, et al.
Publicado: (2022)

Circulating noggin levels following treatment with denosumab or teriparatide in postmenopausal women with low bone mass
por: Anastasilakis, Athanasios D., et al.
Publicado: (2019)

Denosumab for the treatment of osteoporosis
por: McClung, Michael R.
Publicado: (2017)

Current status and unanswered questions on the use of Denosumab in giant cell tumor of bone
por: Gaston, Czar Louie, et al.
Publicado: (2016)

Progress on Denosumab Use in Giant Cell Tumor of Bone: Dose and Duration of Therapy
por: Xiang, Feifan, et al.
Publicado: (2022)

Future of bisphosphonates and denosumab for men with advanced prostate cancer
por: Iranikhah, Maryam, et al.
Publicado: (2014)

The Role of Denosumab for Surgical Outcomes in Patients with Giant Cell Tumour of Bone: A Systematic Review
por: Gupta, Abha, et al.
Publicado: (2021)

Denosumab in pediatric bone disorders and the role of RANKL blockade: a narrative review
por: Wang, Daoxi, et al.
Publicado: (2023)

Use of Denosumab in Children With Osteoclast Bone Dysplasias: Report of Three Cases
por: Upfill‐Brown, Alexander, et al.
Publicado: (2019)

A Retrospective Analysis of Denosumab for the Treatment of Bone Metastases in Chinese Patients With Breast Cancer
por: Li, Wei, et al.
Publicado: (2023)

Amelioration of Paget Disease of Bone After Denosumab for Osteopenia
por: Kamalumpundi, Vijayvardhan, et al.
Publicado: (2023)

Effects of Denosumab on Bone Metabolic Markers and Bone Mineral Density in Patients Treated with Glucocorticoids
por: Sawamura, Masato, et al.
Publicado: (2017)

Denosumab: A comprehensive review
por: Narayanan, Prasad
Publicado: (2013)

The Effect of Denosumab in Elderly Patients Regarding Bone Density and Fracture Risk
por: Yoon, Sung-Hyun, et al.
Publicado: (2023)

Heterogeneity of Circulating Tumor Cell Neoplastic Subpopulations Outlined by Single-Cell Transcriptomics
por: Pauken, Christine M., et al.
Publicado: (2021)

Osteoporosis in men: epidemiology and treatment with denosumab
por: Sidlauskas, Kristel M, et al.
Publicado: (2014)

A review of denosumab for the treatment of osteoporosis
por: Miyazaki, Tsuyoshi, et al.
Publicado: (2014)

Prevention of bone metatasis in prostate cancer by denosumab: Unneeded endpoint or unmet need?
por: Ohlmann, Carsten-Henning
Publicado: (2012)

Denosumab: Delay of bone metastasis in men with nonmetastatic castrate-resistant prostate cancer
por: Manger, Jules P., et al.
Publicado: (2012)

Utilities associated with subcutaneous injections and intravenous infusions for treatment of patients with bone metastases
por: Matza, Louis S, et al.
Publicado: (2013)

Effects of Long-Term Denosumab on Bone Histomorphometry and Mineralization in Women With Postmenopausal Osteoporosis
por: Dempster, David W, et al.
Publicado: (2018)

Denosumab-associated jaw bone necrosis in cancer patients: retrospective descriptive case series study
por: Kang, Ji-Yeon, et al.
Publicado: (2023)

Developing Questions to Assess and Measure Patients’ Perceived Survival Benefit from Adjuvant Endocrine Therapy in Breast Cancer: A Mixed Methods Pilot Study
por: Tawfik, Bernard, et al.
Publicado: (2023)

'Salvage Treatment' of Aggressive Giant Cell Tumor of Bones with Denosumab
por: Vaishya, Raju, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_gdtehj8c3m64mt7hpcqn3g8s3s